OBJECTIVE: To assess the quality of pre-antiretroviral therapy (ART) care in Cape Town and its continuity with HIV counselling and testing (HCT) and ART. METHODS: The scale-up of the HCT, pre-ART and ART service platform and programmatic support in Cape was described. Data from the August 2010 routine annual HIV/TB/STI evaluation, which included interviews with 133 facility managers and folder reviews of 634 HCT clients who tested positive and 1115 clients receiving pre-ART HIV care, were analysed. RESULTS: Historically, the implementation and management of pre-ART care has been relatively neglected compared with the scale-up of HCT and ART. CD4 counts were carried out for 77.5% of positive HCT clients, and 46.6% were clinically staged - crucial steps that determine the care path. There were gaps in quality of care (32.2% of women had a PAP smear), missed opportunities for integrated care (67% were symptomatically screened for tuberculosis) and positive prevention (48.3% had contraceptive needs assessed). Breaks in the continuity of care of pre-ART clients occurred with only 47.2% of eligible clients referred appropriately to the ARV service. CONCLUSION: While a package of pre-ART care is clearly defined in Cape Town, it has not been fully implemented. There are weaknesses in the continuity and quality of service delivered that undermine the programme objectives of provision of positive prevention and timely access to ART.
OBJECTIVE: To assess the quality of pre-antiretroviral therapy (ART) care in Cape Town and its continuity with HIV counselling and testing (HCT) and ART. METHODS: The scale-up of the HCT, pre-ART and ART service platform and programmatic support in Cape was described. Data from the August 2010 routine annual HIV/TB/STI evaluation, which included interviews with 133 facility managers and folder reviews of 634 HCT clients who tested positive and 1115 clients receiving pre-ART HIV care, were analysed. RESULTS: Historically, the implementation and management of pre-ART care has been relatively neglected compared with the scale-up of HCT and ART. CD4 counts were carried out for 77.5% of positive HCT clients, and 46.6% were clinically staged - crucial steps that determine the care path. There were gaps in quality of care (32.2% of women had a PAP smear), missed opportunities for integrated care (67% were symptomatically screened for tuberculosis) and positive prevention (48.3% had contraceptive needs assessed). Breaks in the continuity of care of pre-ART clients occurred with only 47.2% of eligible clients referred appropriately to the ARV service. CONCLUSION: While a package of pre-ART care is clearly defined in Cape Town, it has not been fully implemented. There are weaknesses in the continuity and quality of service delivered that undermine the programme objectives of provision of positive prevention and timely access to ART.
Authors: Catrina Mugglin; Janne Estill; Gilles Wandeler; Nicole Bender; Matthias Egger; Thomas Gsponer; Olivia Keiser Journal: Trop Med Int Health Date: 2012-09-20 Impact factor: 2.622
Authors: Martin C Were; Jason Kessler; Changyu Shen; John Sidle; Stephen Macharia; John Lizcano; Abraham Siika; Kara Wools-Kaloustian; Ann Kurth Journal: J Acquir Immune Defic Syndr Date: 2015-08-01 Impact factor: 3.731
Authors: Sydney Rosen; Mhairi Maskew; Matthew P Fox; Cynthia Nyoni; Constance Mongwenyana; Given Malete; Ian Sanne; Dorah Bokaba; Celeste Sauls; Julia Rohr; Lawrence Long Journal: PLoS Med Date: 2016-05-10 Impact factor: 11.069
Authors: Jacob Bor; Calvin Chiu; Shahira Ahmed; Ingrid Katz; Matthew P Fox; Sydney Rosen; Manisha Yapa; Frank Tanser; Deenan Pillay; Till Bärnighausen Journal: Trop Med Int Health Date: 2018-01-10 Impact factor: 3.918
Authors: Elizabeth du Toit; Cari van Schalkwyk; Rory Dunbar; Karen Jennings; Blia Yang; David Coetzee; Nulda Beyers Journal: PLoS One Date: 2014-05-07 Impact factor: 3.240
Authors: Sydney Rosen; Matthew P Fox; Bruce A Larson; Papa Salif Sow; Peter D Ehrenkranz; Francois Venter; Yukari C Manabe; Jonathan Kaplan Journal: PLoS Med Date: 2016-08-09 Impact factor: 11.069